well first thing first, be very hesitant shorting little bios unless you know your science very well, among others. you predict this is a pump and dump? who are you? hehe in other words, when you speak, do others listen? hehe
it is possible that those who knew what was coming up already stepped out to the sideline before the readout and are now inching back in. you on the other hand seem to be totally clueless.
but this market is exactly that. savvy folks take money from ignorant proud suckers.
adro is not doing well after this nega development. it is trading way below its ipo price. let's be real
big pharms fail phase 3s frequently enough so name dropping does not work here. and here adro cannot go pass phase 2. and the rest is primarily preclinical. 400 mil in pie in the sky for the best case scenario.
stop the nonsense. be more reasonable with your assessment. we are not kinder level so you know. jeeeeeeeeeee
i bought in recently. i figured that the world is crazy over their pets since they are more lovable than fellow humans and folks will not let their pets suffer and will pay for peace of mind.
also, i give petx management credit. they successfully hookwinked adxs. i support opportunistic capitalism!
long ago adro "researchers" did.
yes, it is helpful that folks can rehash for the mass, but the point is, the point that truly matters is: all that talk is academic until the 2 cos put their tires on the road. essentially, adro is done with this ladd, poetic justice for stolen goods. good for pancreatic patients because there is no more false hope with adro. good for stupid big pharm and bankers so that their money can go to better cos. good for others to realize to optimize one's healthy lifestyle is possibly the best offense one can put up. high fat diet, high alcohol intake, high stress...yup,,you can get nasty cancer from that.
adxs has consistently demoed superior efficacy over standard therapy. not a cure, not a home run, but better than what is available. that is money.
"will" advance or "may" advance as fast as pd1? big difference. be more precise with your language and be more sensible, esp at a time when adro needs to reestablish itself. you make it sound like it is already a given, something frequently seen in risky bio investing...
the last person on that list may be involved with that, although it is not clear: Mark Stein, M.D. is a medical oncologist at the Cancer Institute of New Jersey, specializing in prostate cancer. Dr. Stein is an investigator in a Phase 1/2 trial evaluating AXAL in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).
issac played fast and loose while enriching himself in the process. he did so because some who do not know better supported him financially. janssen guy who signed deals with adro should be fired.
now essentially adro is back to preclinical status.
from scientific angle, it is very much apples vs oranges because the approaches are fundamentally different. for those interested, read about them. they have been grouped together simply because 99% of folks out there do not understand the difference and that listeria is the common link that they can id. sure, they are both morning beverages, but coffee and tea are fundamentally different, possibly doing different things to our bodies after digestion. to many in this world those running for usa presidency are not apples vs oranges either because they all claim to have usa's interest in mind. you get the gist? hehe
it is a stupid study design to start with, putting all eggs into one basket type of thinking. the key point here is that it is a 2b which means nothing to fda let alone fda approval for commercial space. the other key point is statistical power. because the difference is not big enough, the "better" crs 207 did not show statistical superiority. the p value would have been much bigger than .05.
i don't consider adxs director,,,management. board members' job is to do nothing and collect shares. it is a gentleman high way robbery. hehehe